NASDAQ : ORGO
Organogenesis Holdings Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 0.8189 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 105.37M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 98.83M |
| Enterprise Value | 119.69M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 128.67M |
| Shares Outstanding | 128.67M |
| Shares Change (YoY) | -1.00% |
| Shares Change (QoQ) | +0.69% |
| Owned by Insiders (%) | 36.02% |
| Owned by Institutions (%) | 43.87% |
| Float | 61.06M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.22 |
| Forward PS | 0.45 |
| PB Ratio | 0.67 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | 4.74 |
| P/OCF Ratio | 3.09 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 5.74 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.52 |
| Quick Ratio | 2.58 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | 4.93 |
| Debt / FCF | 3.21 |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -25.92% |
| Return on Assets (ROA) | -4.11% |
| Return on Invested Capital (ROIC) | -8.51% |
| Return on Capital Employed (ROCE) | -8.15% |
| Weighted Average Cost of Capital (WACC) | 6.70% |
| Revenue Per Employee | $535,660 |
| Profits Per Employee | -$119,067 |
| Employee Count | 854 |
| Asset Turnover | 1.05 |
| Inventory Turnover | 4.19 |
Taxes
| Measure | Value |
|---|
| Income Tax | 49.39M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.27 |
| 52-Week Price Change | -81.58% |
| 50-Day Moving Average | 1.35 |
| 200-Day Moving Average | 2.37 |
| Relative Strength Index (RSI) | 16.45 |
| Average Volume (20 Days) | 974,976 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 15.59M |
| Short Previous Month | 15.00M |
| Short % of Shares Out | 12.12% |
| Short % of Float | 25.53% |
| Short Ratio (days to cover) | 24.03 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 457.45M |
| Gross Profit | 327.02M |
| Operating Income | -28.50M |
| Pretax Income | -34.77M |
| Net Income | -101.68M |
| EBITDA | -9.70M |
| EBIT | -28.50M |
| Loss Per Share | -$0.80 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 46.10M |
| Total Debt | 66.95M |
| Net Cash | -20.85M |
| Net Cash Per Share | -$0.16 |
| Equity (Book Value) | 288.13M |
| Book Value Per Share | 1.15 |
| Working Capital | 143.34M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 31.97M |
| Capital Expenditures | -11.13M |
| Depreciation & Amortization | 18.80M |
| Net Borrowing | -10.79M |
| Free Cash Flow | 20.84M |
| FCF Per Share | $0.16 |
Margins
| Measure | Value |
|---|
| Gross Margin | 71.49% |
| Operating Margin | -6.23% |
| Pretax Margin | -7.60% |
| Profit Margin | -18.40% |
| EBITDA Margin | -2.12% |
| EBIT Margin | -6.23% |
| FCF Margin | 4.56% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 1.00% |
| Shareholder Yield | 1.00% |
| Earnings Yield | -104.27% |
| FCF Yield | 21.09% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $2.00 |
| Price Target Difference | 160.38% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | -18.89% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.29 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |